Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Achilles Therapeutics ( (ACHL) ) has shared an announcement.
On February 28, 2025, Achilles Therapeutics announced its intention to voluntarily delist its American Depositary Shares from Nasdaq and deregister them from the SEC, with the delisting expected to be effective on March 20, 2025. This decision is part of a broader plan to commence a members’ voluntary liquidation, pending shareholder approval at a General Meeting on March 20, 2025, and will result in the suspension of the company’s obligation to file periodic reports with the SEC.
More about Achilles Therapeutics
Achilles Therapeutics is a company operating in the biotechnology industry, focusing on developing personalized cancer immunotherapies. The company is primarily engaged in creating innovative treatments targeting specific cancer mutations, aiming to provide tailored therapeutic solutions.
YTD Price Performance: 21.93%
Average Trading Volume: 818,363
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $57.13M
Find detailed analytics on ACHL stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money